Down 30%: Does Bell Potter rate this ASX 200 stock as a buy, hold, or sell?

This top broker has given its verdict on the stock.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GrainCorp Ltd (ASX: GNC) shares have had a tough time in 2026.

Since the start of the year, the ASX 200 stock has lost almost a third of its value.

Is this a buying opportunity for investors? Let's see what analysts at Bell Potter are saying about the grain exporter's shares following their decline.

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

Image source: Getty Images

What is the broker saying?

Bell Potter notes that recent industry data has been released and it isn't looking favourable for GrainCorp. It said:

The ABARE Jun'26 east coast crop forecast implies a -27% YoY contraction in the east coast winter crop and a -19% YoY contraction in the southeastern canola crop.

Winter East coast crop forecast: ABARE has issued a June 2026-27 east coast winter crop forecast of 23.8mt (vs. 27.2mt in the pcp and a R5YA of 24.2mt). The forecast is predicated on an acreage forecast of 10,370mHa (vs. Jun'24 of 12.0mHa and R5YA of 11.5mHa) and a yield forecast of 2.29t/Ha (vs. Jun'25 of 2.3t/Ha). The acreage forecast is a 7yr low and the yield projection is broadly comparable with the outcome experienced in similar years when the acreage was in the 10,000- 11,000mHa range.

However, the broker highlights that this crop forecast is notoriously unreliable. It explains:

The June forecast is historically the least accurate, on average it has underestimated the final crop size by ~5% over FY11-25 and in the past 5years has underestimated the final crop outcome by ~19%.

Nevertheless, it has still reduced its profit expectations. The broker adds:

NPAT changes are -1% in FY26e and -15% in FY27e reflecting lower crop receipts and lower canola crush volumes, offset in part by stronger crush margins. Our target price is $5.20ps (prev. $5.90ps) reflecting a view that with a drier bias GNC is likely to trade at a discounted multiple.

Is this ASX 200 stock a buy, hold, or sell?

According to the note, Bell Potter has retained its hold rating on GrainCorp's shares with a reduced price target of $5.20.

This is only marginally higher than the current share price of $5.05.

Commenting on its investment thesis, Bell Potter said:

In the June report we noted a seven year low in east coast winter crop acreage sown and a seven year low in southeastern (VIC/NSW/SA) canola production. Key months are now the August-September window, which are crucial for yield development in a potentially dryer backdrop.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Boys making faces and flexing.
Small Cap Shares

3 ASX small-cap shares to buy: Morgans

ASX small caps are underperforming in 2026, but Morgans sees opportunity with these 3 companies.

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

Three ASX shares to buy right now according to Morgans

One of these shares is tipped to more than double.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 28% in a year, should I buy the dip on Resmed shares right now?

A leading analyst provides his outlook for the beaten-down ResMed share price.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A businessman points to an arrow going up on a graph, indicating a share price rise for an ASX company.
Broker Notes

Up 1,277% in a year, why 4DMedical shares are tipped for more outsized gains

A leading analyst forecasts more outperformance from 4DMedical’s rocketing shares. But why?

Read more »

An oil worker in front of a pumpjack using a tablet.
Broker Notes

Why Woodside shares just got a big buy call

A leading analyst forecasts more outperformance from Woodside’s surging shares.

Read more »

A woman smiles at the outlook she sees through binoculars.
Broker Notes

Buy, hold, sell: 4DMedical, Cochlear, Westpac shares

An expert discusses his views on Westpac shares and 2 other popular ASX 200 stocks.

Read more »

Woman in business suit holds both hands out with a question mark above each hand.
Broker Notes

Buy, hold, sell: Ampol, Lendlease, BHP shares

Let's check out some new ratings on 3 ASX 200 shares today.

Read more »